Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Common Equity (2016 - 2025)

Medifast's Common Equity history spans 16 years, with the latest figure at $198.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 5.33% year-over-year to $198.9 million; the TTM value through Dec 2025 reached $198.9 million, down 5.33%, while the annual FY2025 figure was $198.9 million, 5.33% down from the prior year.
  • Common Equity reached $198.9 million in Q4 2025 per MED's latest filing, down from $214.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $216.0 million in Q1 2022 to a low of $129.5 million in Q2 2022.
  • Average Common Equity over 5 years is $192.2 million, with a median of $200.2 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 66.78% in 2021, then plummeted 33.5% in 2022.
  • A 5-year view of Common Equity shows it stood at $202.5 million in 2021, then fell by 23.43% to $155.0 million in 2022, then grew by 29.95% to $201.5 million in 2023, then increased by 4.28% to $210.1 million in 2024, then fell by 5.33% to $198.9 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Common Equity are $198.9 million (Q4 2025), $214.7 million (Q3 2025), and $216.0 million (Q2 2025).